Drug Profile
Meningococcal vaccine groups A C Y W-135 conjugate - Chongqing Zhifei Biological Products
Alternative Names: A, C, Y, W135 meningococcal polysaccharide conjugate vaccine; MenwayconLatest Information Update: 11 Feb 2022
Price :
$50
*
At a glance
- Originator Chongqing Zhifei Biological Products
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 11 Feb 2022 Meningococcal vaccine groups A C Y W-135 conjugate development is ongoing China (NCT05229536)
- 21 Nov 2019 Chongqing Zhifei Biological Products completes a phase II trial in Meningococcal group A, C, Y, W-135 infections (Prevention) in China (IM) in November 2019(NCT05229536)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Meningococcal-group-A-infections(Prevention, In volunteers) in China (IM, Injection)